Talk:Motivation and emotion/Book/2022/Psilocybin assisted psychotherapy

Comment
Hey! I found this reference that discusses safety and risks of psilocybin and I thought it might be relevant to your topic. Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin–summary of knowledge and new perspectives. European Neuropsychopharmacology, 24(3), 342-356. https://doi.org/10.1016/j.euroneuro.2013.12.006--BenRoss068 (discuss • contribs) 04:20, 12 October 2021 (UTC)

Comment
Hello! There is lots of fascinating new research surrounding the use of psilocybin alongside CBT in treating addiction. Here's an interesting longitudinal study. Although it has a small sample size (n=15) the 12-month follow up seems to have resulted in quite high rates of smoking cessation (67% had quit smoking after 12 month follow-up). I hope that this can help direct some of your book chapter and I wish that I was assigned to one as interesting and cutting edge as yours! https://doi.org/10.3109/00952990.2016.1170135 Noah O'Brien (discuss • contribs) 25 August 2022 (UTC)

Comment
Back again to have a quick look at how your chapter is progressing. I think that one of your sentences in your overview should be a little more nuanced "There is no evidence that current anti-depressants and SSRI’s improve depression and anxiety" Possibly indicate that this is a contentious topic and there is a lot of meta-analysis pointing both ways rather than a really bold statement. Maybe more info on how SSRIs seem to produce a similar effect to placebos but not that there is no benefit whatsoever, because there are actually benefits of placebos. This article here shows that there may be a small effect of SSRIs on Major Depressive Disorder, but that the risks of using SSRIs may outweigh the benefits in regards to increased suicidal behaviour etc. Maybe expand into this topic a little. https://doi.org/10.1186/s12888-016-1173-2 Noah O&#39;Brien (discuss • contribs) 06:09, 16 October 2022 (UTC)

-- Jtneill - Talk - c 04:54, 31 August 2021 (UTC)

Comment
Suggest narrowing the topic to a focus on a particular type of disorder for psilocybin assisted psychotherapy, e.g. PTSD or alcoholism. U3191488 (discuss • contribs) 13:23, 28 August 2022 (UTC)

Heading casing
-- Jtneill - Talk - c 09:57, 26 September 2022 (UTC)

Comment
Hey,

Your topic is incredibly intriguing. I would like to add a suggestion: A crucial point you might be missing regarding the negative risks of psilocybin is its risk of causing mental illness. Although it presents an interesting new up and coming therapeutic tool, those with a history of schizophrenia or psychosis are likely to encourage drug induced mental illness even if it is controlled. I found a source supporting this point. I would love to hear your thoughts on this as well :).

https://www.tandfonline.com/doi/abs/10.1080/15622970410029908 U3210431 (discuss • contribs) 07:01, 5 October 2022 (UTC)

Comment
Hi,

I find your topic very interesting and have enjoyed reading what you have so far on your topic. I noticed you have not yet added external links to your chapter. I have done some research and found a few sources that may be of interest to you as they may be relevant to include in your chapter.

The science of psilocybin and its use to relieve suffering (Youtube)

The future of psychedelic-assisted psychotherapy (Youtube) U3190094 (discuss • contribs) 23:42, 9 October 2022 (UTC)

-- Jtneill - Talk - c 03:04, 6 November 2022 (UTC)

-- Jtneill - Talk - c 01:29, 13 November 2022 (UTC)